Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Study:

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rationale:

n/a

Purpose:

The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for reducing total mortality in patients with untreated or incompletely treated AF.

Study Status: Recruiting

Recruiting:
Raquel Rozich rozichr@ccf.org

Condition Intervention Phase
Atrial Fibrillation
Arrhythmia
Device: Left atrial ablation
Drug: Rate or Rhythm Control Therapy
N/A

Verified by Mayo Clinic March, 2013

Sponsored by: Mayo Clinic
Information provided by: Mayo Clinic
ClinicalTrials.gov identifier: NCT00911508

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44193
United States

Douglas L. Packer, M.D.., Principal Investigator
Kerry L. Lee, Ph.D.., Principal Investigator
Daniel B. Mark, M.D., MPH., Principal Investigator
Rich A. Robb, Ph.D. Phy., Principal Investigator
Alice M. Mascette, M.D.., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site